argenx SEARGX

argenx SE (ARGX) is focused on immunology. The company's drug, Vyvgart, has been evaluated in clinical trials, with safety findings reported across various studies. For instance, in the ARGX-113-2002 trial, grade 3 lymphocyte count decreased in 7.5% of participants, and grade 4 lymphocyte count decreased in 0.6% of participants. Another trial, ARGX-113-2001, reported grade 3 clinical laboratory abnormalities of lymphocyte count decreased in 4.5% of participants.

Safety data from the EMA EPAR variation assessment report also indicate specific adverse events. For example, 0.3% of participants experienced grade 3 Clostridium difficile colitis, and 0.3% had grade 3 Urinary tract infection. Grade 3 COVID-19 pneumonia was observed in 0.6% of participants, while grade 4 AESIs occurred in 0.9% of participants. In terms of overall adverse events, 28.9% of males experienced TEAE of CTCAE severity Grade ≥3, compared to 16.2% of females.